Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 9Pain 8Pain, Postoperative 5Breast Neoplasms 5Depression 4Agnosia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pain, Intractable 2Chronic Pain 2Acute Pain 2Prostatic Neoplasms 1Postoperative Analgesia 1Peripheral Nervous System Diseases 1Pelvic Neoplasms 1Pancreatic Neoplasms 1Neurotoxicity Syndromes 1Neuralgia 1Mucositis 1Lymphoma, Follicular 1Lung Neoplasms 1Hypoxia 1Head and Neck Neoplasms 1Emergence Delirium 1Depressive Disorder, Major 1Colorectal Neoplasms 1Colonic Neoplasms 1Choledocholithiasis 1Choledochal Cyst 1Cholangitis 1Cancer Pain 1

Interventions

Midazolam 1Meperidine 1Ketamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cholangitis × Ketamine × Clear all
NCT06111872 2025-03-25

Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography.

National University of Malaysia

Phase 2 Completed
90 enrolled
Gastrointestinal

Cholangitis, Pancreatic Neoplasms, Choledochal Cyst, Choledocholithiasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡